STroke secondary prevention with catheter ABLation and EDoxaban for patients with non-valvular atrial fibrillation - STroke secondary prevention with catheter ABLation and EDoxaban for patients with non-valvular atrial fibrillation: STABLED study

ippon Medical School Hospital0 个研究点目标入组 250 人开始时间: 2018年3月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients who have symptomatic paroxysmal atrial fibrillation and drug resistant 2) Patients who have Left Atrial Thrombus and left atrial appendage by transthoracic echocardiography, Computed Tomography(CT),Magnetic Resonance Imaging(MRI) 3) Patients who have a tendency to bleed or bleed and are considered to be at high risk of bleeding due to anticoagulation therapy. For other reasons, patients who cannot conduct anticoagulation therapy 4) Patients who are suffering from severe renal disorder (Ccr*<30mL/min) *Cockroft-Gault Equation 5) Patients who have undergone catheter ablation or surgical intervention for AF 6) Patients who have a treatment history with left atrial appendage closure device 7) Patients who have a left atrial diameter;55mm<= with transthoracic echocardiography 8) Patients who have ejection fraction;35%>= with transthoracic echocardiography 9) Persistent non-valvular atrial fibrillation over 10 years 10)Patients who have atrial septal defect 11) Patients who are pregnant and of child-bearing potential 12) Patients who are unlikely to complete research, such as progressive malignant tumor 13) Patients who is being participated or will be participated to other clinical trials 14) Patients who do not agree the study inclusion 15) Patients judged as inappropriate for this study by investigators

发起方

ippon Medical School Hospital